Double-blind, Randomized, Active-controlled, Two-way Cross-over Study, With 12-week Treatment Duration Per Period, to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate / Mometasone Furoate) Compared to Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
Latest Information Update: 28 May 2025
At a glance
- Drugs Indacaterol/mometasone (Primary) ; Budesonide
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 21 May 2025 Planned End Date changed from 28 Aug 2028 to 30 May 2028.
- 17 Apr 2025 Planned End Date changed from 11 Jun 2026 to 28 Aug 2028.
- 17 Apr 2025 Planned primary completion date changed from 14 May 2026 to 1 Feb 2028.